健择加顺铂联合化疗治疗晚期鼻咽癌的疗效观察  

Response and Toxicity of the Gemcitabine Plus Cisplatin in Treating the Advanced Nasopharyngeal Carcinoma

作　　者：刘通[1] 冯丽丽[1] 池桂玲[1] 

机构地区：[1]广东省潮州市中心医院肿瘤内科,广东潮州521000

出　　处：《河北医学》2008年第5期556-558,共3页Hebei Medicine

摘　　要：目的：观察健择加顺铂治疗晚期鼻咽癌的疗效和毒副作用。方法：吉西他滨1000mg/m^2dl、d8＋生理盐水100ml静脉点滴30min完成；DDP100mg＋生理盐水500ml静脉滴注,dl,或DDP30mg＋生理盐水250ml静脉滴注，d1～d3，方案每3周为一周期。结果：17例患者完全缓解（CR）2例，部分缓解（PR）11例，总有效率（CR＋PR）达76．5％。主要毒副反应为骨髓抑制（对血小板抑制尤为明显）、消化道反应、轻度肝肾功能损及口腔炎等。结论：健择联合顺铂方案治疗复发或转移性鼻咽癌有效率高和耐受性良好，值得临床进一步研究。Objective： To evaluate the response and toxicity of gemcitabine plus cisplatin in advanced 100mg/m^2 in dl or cisplatin 30mg/m^2 in d1-3 of each three weeks. Result： 17 patients were enrolled. 2 achieved CR and II PR. Response rate was 76.5%. The major toxicity was bone marrow suppression, especially suppression of the thrombocyte. Other toxicity included nausea, vomitus, abnormal of the live and kidney function and stomatitis. Conclusion： For the relapse and metastasis nasopharyngeal carcinoma, gemcit-abine plus cisplatin has good response and well tolerated.

关 键 词：鼻咽癌 联合治疗 疗 效 

分 类 号：R739.63[医药卫生—肿瘤]